Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gynecologic 2Head & Neck 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1

Conditions

Ovarian Neoplasms 33Fallopian Tube Neoplasms 21Endometrial Neoplasms 17Uterine Cervical Neoplasms 13Colorectal Neoplasms 12Neoplasm Metastasis 10Pancreatic Neoplasms 9Prostatic Neoplasms 8Melanoma 8Lung Neoplasms 8Carcinoma, Renal Cell 7Stomach Neoplasms 6Carcinosarcoma 6Carcinoma, Hepatocellular 6Carcinoma, Transitional Cell 5Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 5Triple Negative Breast Neoplasms 4Papillomavirus Infections 4Esophageal Neoplasms 4Sarcoma 3Rectal Neoplasms 3Colonic Neoplasms 3Vulvar Neoplasms 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Sarcoma, Kaposi 2Pelvic Neoplasms 2

Interventions

Nivolumab 3Specimen Handling 2Magnetic Resonance Spectroscopy 2Ipilimumab 2CTLA-4 Antigen 2sintilimab 1serabelisib 1sapanisertib 1rucaparib 1pembrolizumab 1palbociclib 1olaparib 1durvalumab 1ceralasertib 1adavosertib 1Therapeutics 1Restraint, Physical 1Radiation, Ionizing 1Radiation 1Platinum 1Paclitaxel 1Megestrol Acetate 1Medroxyprogesterone Acetate 1Fulvestrant 1Congresses as Topic 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Endometrioid × Specimen Handling × Gynecologic × Clear all
NCT02834013 2026-06-03

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
798 enrolled
CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT05112601 2026-04-21

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
81 enrolled
Gynecologic

Endometrial Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡